Zimmer Biomet (NYSE:ZBH) Updates FY 2026 Earnings Guidance

Zimmer Biomet (NYSE:ZBH - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 8.400-8.550 for the period, compared to the consensus earnings per share estimate of 8.390. The company issued revenue guidance of $8.4 billion-$8.6 billion, compared to the consensus revenue estimate of $8.5 billion.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $92.57 on Tuesday. The firm has a market cap of $17.92 billion, a PE ratio of 26.15, a price-to-earnings-growth ratio of 1.87 and a beta of 0.61. The firm's 50 day simple moving average is $93.52 and its 200-day simple moving average is $92.98. Zimmer Biomet has a one year low of $84.59 and a one year high of $108.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts' consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts predict that Zimmer Biomet will post 8.39 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is 27.12%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ZBH shares. Sanford C. Bernstein raised their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a "market perform" rating in a research report on Friday, January 9th. TD Cowen raised shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a report on Monday, January 26th. Barclays cut their price objective on shares of Zimmer Biomet from $104.00 to $100.00 and set an "underweight" rating on the stock in a report on Thursday, February 12th. William Blair initiated coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a "market perform" rating on the stock. Finally, The Goldman Sachs Group lowered shares of Zimmer Biomet from a "neutral" rating to a "sell" rating and set a $93.00 price objective on the stock. in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $105.95.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company's stock, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC acquired a new stake in Zimmer Biomet in the second quarter valued at approximately $232,000. United Bank boosted its stake in Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock valued at $1,085,000 after acquiring an additional 1,153 shares in the last quarter. Federated Hermes Inc. boosted its stake in Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock valued at $194,000 after acquiring an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC boosted its stake in Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock valued at $7,004,000 after acquiring an additional 37,116 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.